Indication
As monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH):
- In patients with haemolysis with clinical symptom(s) indicative of high disease activity.
- In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.
Medicine details
- Medicine name:
- crovalimab (Piasky)
- SMC ID:
- SMC2728
- Pharmaceutical company
- Roche
- BNF chapter
- Nutrition and blood
- Submission type
- Abbreviated
- Publication due date:
- 13 January 2025